Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (-/-) CF-1 mice

Pharmaceutical Research

Volumn 22, Issue 11, 2005, Pages 1898-1905

  De Oliveira, Manuela Pereira ^a   Garcion, Emmanuel ^b   Venisse, Nicolas ^a,c   Benoît, Jean Pierre ^b   Couet, William ^a,c   Olivier, Jean Christophe ^a  

^a Laboratoire de Biochimie   (France)

^b INSERM   (France)

^c Pôle Biologie Santé   (France)

Author keywords

CF 1 mice; Indinavir; P glycoprotein; Solid lipid nanocapsule; Solutol HS15

Indexed keywords

CHOLESTEROL; CRIVIXAN; EXCIPIENT; INDINAVIR; LABRAFAC; LIPOID; LIPOID S75 3; MULTIDRUG RESISTANCE PROTEIN 1; NANOCAPSULE; OCTANOIC ACID DERIVATIVE; SOLID LIPID NANOPARTICLE; SOLUTOL HS 15; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG SCREENING; DRUG UPTAKE; FEMALE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; TESTIS; TISSUE DISTRIBUTION; TISSUE LEVEL;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CAPSULES; CHEMISTRY, PHARMACEUTICAL; FEMALE; INDINAVIR; MALE; MICE; NANOSTRUCTURES; P-GLYCOPROTEINS; TISSUE DISTRIBUTION;

EID: 27144513215     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-005-7147-6     Document Type: Article

References (47)

1. J. S. Lewis C. M. Terriff D. R. Coulston M. W. Garrison 1997 Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus Clin. Ther. 19 187 214
2. R. J. Pomerantz 2002 Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication Clin. Infect. Dis. 34 91 97
3. T. W. Chun A. S. Fauci 1999 Latent reservoirs of HIV: obstacles to the eradication of virus Proc. Natl. Acad. Sci. USA 96 10958 10961
4. D. L. Kolson E. Lavi F. Gonzalvez-Scarano 1998 The effects of human immunodeficiency virus in the central nervous system Adv. Virus Res. 50 1 47
5. H. Zhang G. Dornadula M. Beaumont L. J. Livornese B. Van Uitert K. Henning R. J. Pomerantz 1998 Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy N. Engl. J. Med. 339 1803 1809
6. T. B. Kepler A. S. Perelson 1998 Drug concentration heterogeneity facilitates the evolution of drug resistance Proc. Natl. Acad. Sci. USA 95 11514 11519
7. F. Thiebaut T. Tsuruo H. Hamada M. M. Gottesman I. Pastan M. C. Willingham 1987 Cellular localization of the multidrug resistance gene product in normal human tissues Proc. Natl. Acad. Sci. USA 84 7735 7738
8. C. Cordon-Cardo J. P. O'Brien D. Casals L. Rittman-Grauer J. L. Biedler M. R. Melamed J. R. Bertino 1989 Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood brain barrier sites Proc. Natl. Acad. Sci. USA 86 695 698
9. E. C. de Lange 1989 Potential role of ABC transporters as a detoxification system at the blood-CSF barrier Adv. Drug. Deliv. Rev. 56 1793 1809
10. N. Melaine M. O. Lienard I. Dorval C. Le Goascogne H. Lejeune B. Jegou 2002 Multidrug resistance genes and P-glycoprotein in the testis of the rat, mouse, guinea pig and human Biol. Reprod. 67 1699 1707
11. R. B. Kim M. F. Fromm C. Wandel A. J. Wood D. M. Roden G. R. Wilkinson 1998 The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV protease inhibitors J. Clin. Invest. 101 289 294
12. E. F. Choo B. Leake C. Wandel H. Imamura A. J. Wood G. R. Wilkinson R. B. Kim 2000 Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes Drug Metab. Dispos. 28 655 660
13. J. H. Lin 2004 How significant is the role of P-glycoprotein in drug absorption and brain uptake? Drugs Today (Barc.) 40 5 22
14. A. R. Bender H. von Briesen J. Kreuter I. B. Duncan H. Rubsamen-Waigmann 1996 Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro Antimicrob. Agents Chemother. 40 1467 1471
15. J. F. Gagne A. Desormeaux S. Perron M. J. Tremblay M. G. Bergeron 2002 Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes Biochim. Biophys. Acta 1558 198 210
16. B. Heurtault, P. Saulnier, B. Pech, J. E. Proust, J. Richard, J. P. Benoit. A novel phase inversion-based process for the preparation of lipidic nanocarriers, 2000. Patent FR 0002688.
17. A. Cahouet B. Denizot F. Hindre C. Passirani B. Heurtault M. Moreau J. Le Jeune J. P. Benoit 2002 Biodistribution of dual radiolabeled lipidic nanocapsules in the rat using scintigraphy and gamma counting Int. J. Pharm. 242 367 371
18. J. S. Coon W. Knudson K. Clodfelter B. Lu R. S. Weinstein 1991 Solutol HS 15, non toxic polyethylene esters of 12-hydroxystearic acid reverses multidrug resistance Cancer Res. 51 897 902
19. L. E. Buckingham M. Balasubramanian A. R. Safa H. Shah P. Komarov R. M. Emanuele J. S. Coon 1996 Reversal of multi-drug resistance in vitro by fatty acid-PEG-fatty acid diester Int. J. Cancer 65 74 79
20. R. C. Bravo Gonzalez J. Huwyler F. Boess I. Walter B. Bittner 2004 In vitro investigation on the impact of the surface-active excipients Cremophor EL, Tween 80 and Solutol HS 15 on the metabolism of midazolam Biopharm. Drug Dispos. 25 37 49
21. L. Y. Li G. L. Amidon J. S. Kim T. Heimbach F. Kesisoglou J. T. Topliss D. Fleisher 2002 Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in rat J. Pharmacol. Exp. Ther. 301 586 593
22. F. L. S. Tse 1995 Pharmacokinetics in drug discovery and development: nonclinical studies P. G. Welling F. L. S. Tse Pharmacokinetics: Regulatory, Industrial, Academic Perspectives 2 Marcel Dekker New York 281 334
23. E. Y. Wu J. M. Wilkinson D. G. Naret V. L. Daniels L. J. Williams D. A. Khalil B. V. Shetty 1997 High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma J. Chromatogr. B Biomed. Sci. Appl. 695 373 380
24. R. P. van Heeswijk R. M. Hoetelmans R. Harms P. L. Meenhorst J. W. Mulder J. M. Lange J. H. Beijnen 1998 Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection J. Chromatogr. B Biomed. Sci. Appl. 719 159 168
25. J. Chi A. L. Jayewardene J. A. Stone T. Motoya F. T. Aweeka 2002 Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS J. Pharm. Biomed. Anal. 30 675 684
26. J. M. Croop M. Raymond D. Haber A. Devault R. J. Arceci P. Gros D. E. Housman 1989 The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues Mol. Cell Biol. 9 1346 1350
27. T. R. Pippert D. R. Umbenhauer 2001 The subpopulation of CF-1 mice deficient in P-glycoprotein contains a murine retroviral insertion in the mdr1a gene J. Biochem. Mol. Toxicol. 15 83 89
28. E. G. Schuetz D. R. Umbenhauer K. Yasuda C. Brimer L. Nguyen M. V. Relling J. D. Schuetz A. H. Schinckel 2000 Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes Mol. Pharmacol. 57 188 197
29. G. R. Lankas M. E. Cartwright D. Umbenhauer 1997 P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances ivermectin-induced neurotoxicity Toxicol. Appl. Pharmacol. 143 357 365
30. J. A. Bush G. Li 2002 Regulation of the mdr1 isoforms in a p53-deficient mouse model Carcinogenesis 23 1603 1607
31. N. Mizuno T. Niwa Y. Yotsumoto Y. Sugiyama 2003 Impact of drug transporter studies on drug discovery and development Pharmacol. Rev. 55 425 461
32. A. H. Schinkel U. Mayer E. Wagenaar C. A. Mol L. van Deemter J. J. Smit M. A. van der Valk A. C. Voordouw H. Spits O. van Tellingen J. M. Zijlmans W. E. Fibbe P. Borst 1997 Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins Proc. Natl. Acad. Sci. USA 94 4028 4033
33. J. A. Holash S. I. Harik G. Perry P. A. Stewart 1993 Barrier properties of testis microvessels Proc. Natl. Acad. Sci. USA 90 11069 11073
34. J. van Asperen O. van Tellingen F. Tijssen A. H. Schinkel J. H. Beijnen 1999 Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein Br. J. Cancer 79 108 113
35. J. Jodoin M. Demeule L. Fenart R. Cecchelli S. Farmer K. J. Linton C. F. Higgins R. Beliveau 2003 P-glycoprotein in blood-brain barrier endothelial cells: interaction and oligomerization with caveolins J. Neurochem. 87 1010 1023
36. M. T. Huisman J. W. Smit K. M. Crommentuyn N. Zelcer H. R. Wiltshire J. H. Beijnen A. H. Schinkel 2002 Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors and transport can enhanced by other drugs AIDS 16 2295 2301
37. A. Rosati S. Maniori G. Decorti L. Candussio T. Giraldi F. Bartoli 2003 Physiological regulation of P-glycoprotein MRP1, MRP2 and cytochrome P 450 3A2 during rat ontogeny Dev. Growth Differ. 45 377 387
38. A. S. Chong P. N. Markham H. M. Gebel S. D. Bines J. S. Coon 1993 Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cells Cancer Immunol. Immunother. 36 133 139
39. K. Buszello S. Harnisch R. H. Muller B. W. Muller 2000 The influence of alkali fatty acids on the properties and the stability of parenteral O/W emulsions modified with Solutol HS15 Eur. J. Pharm. Biopharm. 49 143 149
40. K. Woodburn E. Sykes D. Kessel 1995 Interactions of Solutol HS 15 and Cremophor EL with plasma lipoproteins Int. J. Biochem. Cell. Biol. 27 693 699
41. L. E. Buckingham M. Balasubramanian R. M. Emanuele K. E. Clodfelter J. S. Coon 1995 Comparison of Solutol HS 15, Cremophor EL and novel ethoxylated fatty acid surfactants as multidrug resistance modification agents Int. J. Cancer 62 436 442
42. P. G. Komarov A. A. Shtil L. E. Buckingham M. Balasubramanian O. Piraner R. M. Emanuele I. B. Roninson J. S. Coon 1996 Inhibition of cytarabine-induced MDR1 (P-glycoprotein) gene activation in human tumor cells by fatty acid-polyethylene glycol-fatty acid diesters, novel inhibitors of P-glycoprotein function Int. J. Cancer 68 245 250
43. B. Bittner R. C. Gonzalez I. Walter M. Kapps J. Huwyler 2003 Impact of Solutol HS 15 on the pharmacokinetic behaviour of colchicine upon intravenous administration to male Wistar rats Biopharm. Drug Dispos. 24 173 181
44. B. Bittner R. C. Gonzalez H. Isel C. Flament 2003 Impact of Solutol HS 15 on the pharmacokinetic behavior of midazolam upon intravenous administration to male Wistar rats Eur. J. Pharm. Biopharm. 56 143 146
45. P. R. Lockman J. Koziara K. E. Roder J. Paulson T. J. Abbruscato R. J. Mumper D. D. Allen 2003 In vivo and in vitro assessment of baseline blood-brain barrier parameters in the presence of novel nanoparticles Pharm. Res. 56 705 713
46. A. Vonarbourg P. Saulnier C. Passirani J. P. Benoit 2005 Electrokinetic properties of noncharged lipid nanocapsules: influence of the dipolar distribution at the interface Electrophoresis 26 2066 2075
47. P. K. Dudeja K. M. Anderson J. S. Harris L. Buckingham J. S. Coon 1995 Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity Arch Biochem. Biophys. 319 309 315